Noxopharm Limited (ASX:NOX)
0.0680
+0.0030 (4.62%)
At close: Mar 3, 2026
Noxopharm Revenue
Noxopharm had revenue of 1.66M AUD in the half year ending June 30, 2025, a decrease of -37.52%. This brings the company's revenue in the last twelve months to 2.68M, down -22.98% year-over-year. In the fiscal year ending June 30, 2025, Noxopharm had annual revenue of 2.82M with 17.52% growth.
Revenue (ttm)
2.68M
Revenue Growth
-22.98%
P/S Ratio
7.80
Revenue / Employee
n/a
Employees
n/a
Market Cap
20.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 2.82M | 420.56K | 17.52% |
| Jun 30, 2024 | 2.40M | -3.61M | -60.06% |
| Jun 30, 2023 | 6.01M | 581.44K | 10.71% |
| Jun 30, 2022 | 5.43M | -179.61K | -3.20% |
| Jun 30, 2021 | 5.61M | -2.67M | -32.29% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 7.48M |
| Neurotech International | 7.07M |
| Tissue Repair | 3.26M |
| Avecho Biotechnology | 1.24M |
| Argenica Therapeutics | 1.01M |
| AdAlta | 608.07K |
| Bio-Gene Technology | 390.63K |
| NeuroScientific Biopharmaceuticals | 341.16K |